Imperagen Limited

Established in 2021, Imperagen is a pioneering Techbio company, focused on accelerating the process of enzyme engineering. Serving diverse markets, from pharmaceutical manufacturing and life sciences to sustainable fine chemical production and industrial applications, we work hand-in-hand with our customers to de-risk and streamline their product development and fast track their path to market.

At the heart of our approach is our Digital Enzyme Evolution^TM technology – a fully integrated, digitialized platform that revolutionizes enzyme development. By unifying AI-led protein design with novel biotechnology and laboratory automation, it  enables the creation of high-performance enzymes with unprecedented speed, accuracy and reliability.

Our leadership team brings over 100 years of combined experience in biotech R&D and commercialisation, with a highly talented research team that spans synthetic biology, chemistry, and computational science. We operate out of our state-of-the-art facilities in Manchester, UK — home to the Manchester Institute of Biotechnology and the Alan Turing Institute —the world’s original industrial city and now a thriving global-hub for biotechnology and digital innovation.

We’re proud to be backed by visionary UK-based investors IQ Capital and Northern Gritstone, who share our commitment to leveraging digitalization to transform biotechnology and help our customers deliver truly transformative products.

• Enzyme